[Transfusion of blood with HL-A type. A study with 2,380 donors (author's transl)].
Patients receiving repeated transfusions sooner or later develop an anti-HL-A immunization. To prevent or to delay this immunization by transfusing "deleucocyted" blood appears in the long run, to be a vague hope. So, it became essential to use blood from donors typed for the HL-A system. In this study we have examined what would happen if a pool of 2,380 HL-A type donors were available for 110 recipients. Twenty five per cent of the recipients will have blood available from more than 5 donors with the same HL-A types as themselves, and 71% of them can receive blood from more than 5 donors sharing at least one antigen at each locus (and with no antigen known to be different between them).
D000740:Anemia / Q000628:therapy; D000917:Antibody Formation; D001782:Blood Donors; D001803:Blood Transfusion; D006680:HLA Antigens; D006649:Histocompatibility Antigens; D006650:Histocompatibility Testing; D006801:Humans; D007970:Leukopenia / Q000628:therapy; D013921:Thrombocytopenia / Q000628:therapy; D065227:Transfusion Reaction
D006680:HLA Antigens; D006649:Histocompatibility Antigens
Transfusion de sang sélectionné sur base du phénotype HL-A. Estimation des possibilités offertes par une population de 2 380 donneurs